TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral Rehabilitation
Description: Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo flexibility exercise
Description: Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
Study: NCT00617136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative warming (Bair Hugger)
Description: Intraoperative warming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre- and intraoperative warming (HotDog)
Description: Pre- and intraoperative warming by HotDog

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative warming (HotDog)
Description: Intraoperative warming
Study: NCT00713817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
Study: NCT03846349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPI
Description: IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EMT threshold
Description: EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
Study: NCT03420079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-411 Dose-escalation
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-411 Dose-expansion
Description: * FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR.
Study: NCT03987724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging at rest and during supine bicycle exercise
Description: Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
Study: NCT04667910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 601 1.25mg
Description: Solution for injection (intravitreal use)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizuman 0.5 mg
Description: Solution for injection (intravitreal use)
Study: NCT02863731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating working postures, first day
Description: On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating working postures, second day
Description: On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
Study: NCT02000596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy with Anastrozole and Fulvestrant
Description: Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
Study: NCT01246596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental root planing
Description: The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental root planing
Description: The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
Study: NCT02461134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
Study: NCT02751853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheter
Description: Continuous online measurements of left ventricular pressure and volume using conductance catheters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheter
Description: Continuous online measurements of left ventricular pressure and volume using conductance catheters

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conductance catheter
Description: Continuous online measurements of left ventricular pressure and volume using conductance catheters
Study: NCT03310918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Leukemia care
Description: Standard care per the hospital guideline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Leukemia care
Description: Standard care per the hospital guideline
Study: NCT03791814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Patients screened as HCV positive will receive Zepatier for 12 weeks.
Study: NCT02243995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Study: NCT01764906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novosis
Study: NCT02000596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Eribulin
Study: NCT00201968

Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill

Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Exercise
Description: An aerobic and resistance training program.
Study: NCT02080351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task
Study: NCT01825642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve-sparing radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: seminal vesicle-sparing radical prostatectomy
Study: NCT02614391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active distraction using a tablet
Description: Playing a videogame using a computer tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive distraction
Description: A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
Study: NCT02423304

Intervention type: GENETIC
Intervention: blood samples collected from all patients
Description: blood samples collected from brachial pluxes

Intervention type: GENETIC
Intervention: blood samples collected from all patients
Description: blood samples collected from brachial pluxes
Study: NCT00565591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol sulfate
Description: Single dose dry powder by inhalation
Study: NCT00827684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Study: NCT03034460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024 1% cream
Description: 500 µL on half-face, five days a week during 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD5024 cream placebo
Description: 500 µL on half-face, five days a week during 6 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: CD0271/CD1579 gel
Description: 500 µL on half-face, five days a week during 6 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: CD0271/CD1579 gel placebo
Description: 500 µL on half-face, five days a week during 6 weeks
Study: NCT00745199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cromolyn sodium
Description: oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
Study: NCT05013645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterilized probiotic LfQi601
Description: Sterilized probiotic topically administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel control product
Study: NCT01292382

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
Study: NCT00151970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
Study: NCT03819881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STMC-103H
Description: Live bacterial product

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo substance
Study: NCT04297813

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Advanced medicinal Therapy (MSC combined with biomaterial)
Description: Augmentation of alveolar ridge with MSC and biomaterial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Augmentation of the alveolar ridge with bone graft
Study: NCT03088475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led smartphone-based self-management programme
Description: The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exiting nurse-led diabetes service
Description: the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
Study: NCT01131351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: OPC-67683 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: OPC-67683 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Study: NCT00854698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: subjects are asked to exercise 20 or 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: subjects are asked to exercise during 20 or 30 minutes
Description: subjects are asked to exercise during 20 or 30 minutes
Study: NCT01747967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Test
Description: Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
Study: NCT00715195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plurifocal educational program
Description: intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
Study: NCT01440842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Description: Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV insulin infusion sliding scale
Description: Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
Study: NCT01931748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MELSMON

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNCNT
Study: NCT03371979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT01595984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin + mycophenolate mofetil
Description: antirejection drug, renal transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus + mycophenolate mofetil
Description: antirejection drug, renal transplantation
Study: NCT04853836

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: co-ultraPEALut
Description: Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory Rehab
Description: Olfactory Rehabilitation10 minutes twice a day for all the observation period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEA-LUT 1 sachet
Description: Only 1 sachet day of PEA-LUT no olfactory training

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEA-LUT 2 sachet day
Description: 2 sachets day of PEA-LUT no olfactory training
Study: NCT03094351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: Robot assisted esophagectomy with extended two field lymphadenectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophagectomy
Description: Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
Study: NCT00003042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT03588182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Experience
Description: Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
Study: NCT03886311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
Description: Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab IV Soln 100 MG/10ML
Description: NIVOLUMAB 240 mg IV over 30 min q 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Description: TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
Study: NCT00757536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Encircling Band
Description: ppVE and encircling band

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endolaser Photocoagulation
Description: ppVE and endolaser photocoagulation
Study: NCT01347424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel , carboplatin, endostatin
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
Study: NCT02675816

Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® Upper Airway Stimulation (UAS) System
Description: This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
Study: NCT04302584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine / Vasopressin
Description: • The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine / Vasopressin
Description: • The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
Study: NCT00589498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 extra calories
Description: Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.